Published in Microbiol Spectr on August 01, 2015
Recombinant Adeno-Associated Virus Serotype 6 (rAAV6) Potently and Preferentially Transduces Rat Astrocytes In vitro and In vivo. Front Cell Neurosci (2016) 0.75
Ultramicroscopy as a novel tool to unravel the tropism of AAV gene therapy vectors in the brain. Sci Rep (2016) 0.75
Sequence variants of BIEC2-808543 near LCORL are associated with body composition in Thoroughbreds under training. J Equine Sci (2016) 0.75
Biophysical Properties of Optogenetic Tools and Their Application for Vision Restoration Approaches. Front Syst Neurosci (2016) 0.75
Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell (1987) 20.47
Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med (2008) 17.21
Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med (2008) 15.30
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med (2006) 13.51
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A (2002) 11.11
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 11.01
ADENOVIRUS-ASSOCIATED DEFECTIVE VIRUS PARTICLES. Science (1965) 9.77
Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther (2008) 8.83
Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol (1998) 8.45
Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. Nature (1985) 7.95
Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A (1990) 7.06
CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol (1998) 6.83
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet (2009) 6.71
Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol (1989) 6.69
Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol (1996) 6.43
Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol (1996) 6.22
Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol (1992) 6.16
Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J (1991) 6.13
The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity. Cell (1990) 5.98
Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol (1996) 5.94
Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants. J Virol (1984) 5.89
Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther (2008) 5.83
Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol (2002) 5.82
Evidence for a single-stranded adenovirus-associated virus genome: formation of a DNA density hybrid on release of viral DNA. Proc Natl Acad Sci U S A (1969) 5.78
Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci U S A (1982) 5.73
Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med (1999) 5.50
Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV. Cell (1983) 5.27
AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med (1999) 5.26
Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther (2003) 4.92
Concatemers of alternating plus and minus strands are intermediates in adenovirus-associated virus DNA synthesis. Proc Natl Acad Sci U S A (1976) 4.62
Palindromic base sequences and replication of eukaryote chromosome ends. Nature (1974) 4.33
The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A (2002) 4.30
Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med (2010) 4.28
Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol (1998) 4.17
Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol (2006) 4.12
New recombinant serotypes of AAV vectors. Curr Gene Ther (2005) 3.87
Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol (2000) 3.84
Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A (2008) 3.84
In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol (2008) 3.79
Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol (2011) 3.79
AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood (2009) 3.65
Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol (2004) 3.65
Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci U S A (1994) 3.59
Factors that bind to adeno-associated virus terminal repeats. J Virol (1989) 3.56
Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther (2007) 3.26
Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol (2003) 3.25
In vitro resolution of covalently joined AAV chromosome ends. Cell (1990) 3.24
Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem (2001) 3.15
Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol (1998) 3.14
Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol (2001) 3.11
Self-complementary AAV vectors; advances and applications. Mol Ther (2008) 3.10
Human gene targeting by viral vectors. Nat Genet (1998) 3.02
Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol (2003) 3.01
The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol (2006) 2.94
Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol (2003) 2.93
AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med (2012) 2.87
AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet (2003) 2.81
Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol (2006) 2.79
Detection of adeno-associated virus (AAV)-specific nucleotide sequences in DNA isolated from latently infected Detroit 6 cells. Virology (1975) 2.77
Features of the adeno-associated virus origin involved in substrate recognition by the viral Rep protein. J Virol (1993) 2.69
Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J Virol (2006) 2.63
Evidence for covalent attachment of the adeno-associated virus (AAV) rep protein to the ends of the AAV genome. J Virol (1990) 2.62
Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J Virol (2001) 2.56
Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol (2002) 2.55
Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther (2008) 2.54
Identification of linear DNA sequences that specifically bind the adeno-associated virus Rep protein. J Virol (1994) 2.52
The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol (2002) 2.44
Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med (2003) 2.43
Virus-mediated killing of cells that lack p53 activity. Nature (2001) 2.42
Characterization of adenovirus-associated virus-induced polypeptides in KB cells. J Virol (1978) 2.40
Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet (2004) 2.36
Biologically active Rep proteins of adeno-associated virus type 2 produced as fusion proteins in Escherichia coli. J Virol (1994) 2.32
Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro. J Virol (1997) 2.32
Subcellular compartmentalization of adeno-associated virus type 2 assembly. J Virol (1997) 2.31
Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood (2005) 2.29
Adeno-associated virus vectors integrate at chromosome breakage sites. Nat Genet (2004) 2.27
Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med (1999) 2.24
Identification of a DNA-binding domain in the amino terminus of adeno-associated virus Rep proteins. J Virol (1993) 2.22
DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc Natl Acad Sci U S A (1995) 2.20
Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther (2008) 2.19
Structure of adeno-associated virus serotype 8, a gene therapy vector. J Virol (2007) 2.15
Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. Virology (1984) 2.13
Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A (1996) 2.12
Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol (2008) 2.10
Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol (2005) 2.09
Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther (2012) 2.09
Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail (2008) 2.09
Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol (2009) 2.07
Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res (2006) 2.07
Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther (2011) 2.04
Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J Virol (2000) 2.00
Dynamin is required for recombinant adeno-associated virus type 2 infection. J Virol (1999) 1.99
Sequence requirements for stable binding and function of Rep68 on the adeno-associated virus type 2 inverted terminal repeats. J Virol (1994) 1.98
Interaction of the adeno-associated virus Rep protein with a sequence within the A palindrome of the viral terminal repeat. J Virol (1994) 1.98
Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol (2005) 1.97
Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J Virol (2006) 1.97
Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology (2008) 1.96
Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol (2006) 2.79
Polymeric nanogels produced via inverse microemulsion polymerization as potential gene and antisense delivery agents. J Am Chem Soc (2002) 1.98
Role of viral vectors and virion shells in cellular gene expression. Mol Ther (2004) 1.40
Glucose regulated protein 78 diminishes α-synuclein neurotoxicity in a rat model of Parkinson disease. Mol Ther (2012) 1.24
Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther (2010) 1.24
Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther (2005) 1.19
Identification of cellular proteins that interact with the adeno-associated virus rep protein. J Virol (2008) 1.12
Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction. Proc Natl Acad Sci U S A (2007) 1.12
Single-polarity recombinant adeno-associated virus 2 vector-mediated transgene expression in vitro and in vivo: mechanism of transduction. Mol Ther (2007) 1.10
The prevalence of human parvovirus B19 DNA and antibodies in blood donors from four Chinese blood centers. Transfusion (2011) 1.05
Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. J Virol (2012) 1.04
Oversized AAV transductifon is mediated via a DNA-PKcs-independent, Rad51C-dependent repair pathway. Mol Ther (2013) 1.02
Production of recombinant adeno-associated viral vectors and use in in vitro and in vivo administration. Curr Protoc Neurosci (2011) 0.97
Production of recombinant adeno-associated viral vectors for in vitro and in vivo use. Curr Protoc Mol Biol (2007) 0.97
Replicability of bacterial communities in denitrifying bioreactors as measured by PCR/T-RFLP analysis. Environ Sci Technol (2006) 0.97
Production of recombinant adeno-associated viral vectors. Curr Protoc Hum Genet (2007) 0.83
Production of recombinant adeno-associated viral vectors and use for in vitro and in vivo administration. Curr Protoc Neurosci (2006) 0.82
A detailed characterization of the adult mouse model of glycogen storage disease Ia. Lab Invest (2009) 0.82
Promyelocytic leukemia protein is a cell-intrinsic factor inhibiting parvovirus DNA replication. J Virol (2013) 0.81
Preclinical toxicity evaluation of AAV for pain: evidence from human AAV studies and from the pharmacology of analgesic drugs. Mol Pain (2014) 0.80
Low-field thermal mixing in [1-(13)C] pyruvic acid for brute-force hyperpolarization. Phys Chem Chem Phys (2016) 0.78
Targeted integration by adeno-associated virus. Methods Mol Med (2003) 0.76
Correction: Low-field thermal mixing in [1-(13)C] pyruvic acid for brute-force hyperpolarization. Phys Chem Chem Phys (2016) 0.75